385 related articles for article (PubMed ID: 32253184)
1. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M
Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184
[TBL] [Abstract][Full Text] [Related]
2. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
3. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC
Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
11. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Baraliakos X; Deodhar A; van der Heijde D; Magrey M; Maksymowych WP; Tomita T; Xu H; Massow U; Fleurinck C; Ellis AM; Vaux T; Shepherd-Smith J; Marten A; Gensler LS
Ann Rheum Dis; 2024 Jan; 83(2):199-213. PubMed ID: 37793792
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
16. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
17. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
[TBL] [Abstract][Full Text] [Related]
18. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
Sieper J; Braun J; Kay J; Badalamenti S; Radin AR; Jiao L; Fiore S; Momtahen T; Yancopoulos GD; Stahl N; Inman RD
Ann Rheum Dis; 2015 Jun; 74(6):1051-7. PubMed ID: 24550171
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Baraliakos X; Deodhar A; Dougados M; Gensler LS; Molto A; Ramiro S; Kivitz AJ; Poddubnyy D; Oortgiesen M; Vaux T; Fleurinck C; Shepherd-Smith J; de la Loge C; de Peyrecave N; van der Heijde D
Arthritis Rheumatol; 2022 Dec; 74(12):1943-1958. PubMed ID: 35829672
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
